Feed/Companies/AAVantgarde

AAVantgarde

As of 14 Oct 2026, AAVantgarde has raised $141M across 1 verified round on record; latest: $141 million (€122 million) Series B led by Schroders Capital, announced 3 Nov 2025.

BUILT ON

Visit site

AAVantgarde is a clinical-stage biotechnology company developing next-generation therapies for inherited retinal diseases with high unmet need

aavantgarde.comLinkedInBiotech

LATEST ROUND

Series B

$141M · 2025-11-03

RAISED ON RECORD · USD

$141M

across 1 verified round

INVESTORS

1 lead

SOURCES

from 1 publisher

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Series B

$141M · 2025-11-03

[ HISTORY ]

led by Schroders Capital

Round	Amount	Announced	Lead	Buzz
Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$141M	2025-11-03	Schroders Capital	No recent discussion
1 source [ VERIFIED · CORRECTED ] read against 1 source Removed CDP Venture Capital · no source places them in this round The company release describes Schroders Capital, Atlas Venture, and Forbion as co-leads; the other named firms are participants. The London and Milan dateline does not establish headquarters.

AAVantgarde

Company

Rounds

Sources

Profile

Investors

AAVantgarde

Rounds

Profile

Sources

Series B$141M2025-11-031 source

Investors

Series B$141M2025-11-0313 investors